Niagen Bioscience, Inc. NAGE
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.94% | 10.99% | 20.84% | 29.95% | 36.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.94% | 10.99% | 20.84% | 29.95% | 36.04% |
| Cost of Revenue | -1.86% | 9.11% | 15.12% | 21.63% | 27.40% |
| Gross Profit | -1.99% | 12.07% | 24.27% | 35.08% | 41.47% |
| SG&A Expenses | 26.38% | 30.67% | 34.92% | 30.76% | 8.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.37% | 20.91% | 26.00% | 25.31% | 15.55% |
| Operating Income | -85.54% | -48.32% | -16.09% | 85.04% | 4,218.57% |
| Income Before Tax | -47.98% | -7.10% | 35.11% | 105.44% | 1,331.11% |
| Income Tax Expenses | -0.97% | 72.55% | 123.89% | 165.57% | -- |
| Earnings from Continuing Operations | -49.88% | -9.80% | 32.13% | 103.30% | 1,275.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.88% | -9.80% | 32.13% | 103.30% | 1,275.69% |
| EBIT | -85.54% | -48.32% | -16.09% | 85.04% | 4,218.57% |
| EBITDA | -80.76% | -45.04% | -14.56% | 76.59% | 1,458.93% |
| EPS Basic | -50.75% | -12.12% | 28.10% | 97.93% | 1,240.00% |
| Normalized Basic EPS | -80.16% | -45.43% | -13.89% | 78.33% | 1,304.13% |
| EPS Diluted | -51.06% | -12.55% | 26.65% | 108.42% | 2,312.24% |
| Normalized Diluted EPS | -80.23% | -45.82% | -15.59% | 74.63% | 1,241.53% |
| Average Basic Shares Outstanding | 1.14% | 2.59% | 3.80% | 3.99% | 3.94% |
| Average Diluted Shares Outstanding | -2.10% | 2.80% | 7.43% | 9.77% | 11.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |